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Summary 
We have constructed a soluble chimeric fusion protein between the mouse CD8ot chain and 
the mouse CD40 T cell ligand. This protein binds to both human and mouse B cells. By itself 
it induced a modest degree of B cell proliferation, but together with antiimmunoglobulin (anti- 
Ig) antibody it greatly stimulated B cell proliferation, as determined by both [3H]thymidine 
uptake and increase in cell numbers. These data are evidence that the CD40 ligand on T  cells 
provides  a signal that drives B cell proliferation. This signal is synergistic with that delivered 
by anti-Ig antibody. 
T  cells activated either physiologically by peptide-bound 
MHC molecules (1) or activated in vitro by antibodies 
to CD3 (2) induce vigorous B cell proliferation. This B cell 
proliferation is contact dependent, and can be mimicked at 
least in part by membrane preparations from activated T cells 
(3).  Although the molecules responsible for this activation 
have until recently been poorly understood, the ligand for 
the CD40 molecule in B cells has always been considered a 
likely candidate, mAbs that crosslink CD40 induce B cell 
proliferation, especially in conjunction with other stimuli such 
as antibodies to Ig (4). 
Recently we and others have identified a T cell ligand for 
the CD40 molecule that is a 35-kD protein expressed  as a 
monomer on activated T  cells (5-7).  The cDNA encoding 
this molecule has been cloned (5). Expression of the mouse 
CD40 ligand (mCD40L) in human EBV-transfected  B cells 
stimulated B cell division (5), which was interpreted as indi- 
cating that no other signal was necessary for B cell prolifera- 
tion.  However, it is difficult to exclude other intercellular 
molecular interactions besides the one of interest in systems 
that rely on the expression of transfected molecules. 
Here we describe  the development of a soluble form of 
mCD40L that was obtained by constructing a fusion protein 
from the extracellular portion of the mouse CD8c~ chain and 
the extracellular portion of mCD40L (mCD40L-mCD8ct). 
Materials and Methods 
Construction and Expression of  Soluble mCD4OL-mCDSc~ Chimeric 
Protein.  The primers used to amplify the extracellular portion of 
mouse CD8c~ were: 5'(GGGACGAGAAGCTGAATTCGTCGAA- 
ACTGT), and Y(TCCTCTTCGACCTTATCCAAGGCGAAGTC- 
CAATCCGGTCC). The primers for mouse CD40L were: 5'(GGA- 
C CGGATTGGACTTCGCCTTGGATAAGGTC  GAAGAGGA  ), 
and Y  (TGTGTGAAGCTTAGGACAGCGCACTGTTCA). 
PCR was used to amplify  cDNA encoding the extraceUular  por- 
tion of mouse CD8ct protein together with the extraceUular por- 
tion of mouse CD40L (5). Primers encoding the 3' sequence of 
the CD8 fragment and the 5' portion of mCD40L were designed 
to overlap; annealing of the PCK products yielded a hybrid tem- 
plate. The template encoding the chimeric  construct was selectively 
amplified using external primers specific  for the 5' region of CD8 
and the 3' region of mCD40L, each primer containing appropriate 
restriction sites for subcloning  into the expression vector pH/3 APr- 
1-neo (8). The resulting PCK fragment of ml.3 kb was ligated 
into the expression vector above, and transfected into competent 
Escherichia coli, which were selected on ampicillin-containing agar 
plates. Plasmids from resistant clones ofE. coli containing the cor- 
rectly inserted fragment were identified by digestion with EcoRI 
and HindlII. The resulting plasmid is henceforth called  pH/3 APr- 
1-neo mCD40l~mCD8ct. CD8c~ was chosen because the extracel- 
lular portion has been shown to be readily secreted (9). 
Construction of Chimeric Human IgG1 Molecules.  The primers 
used to amplify the extracellular portion  of the mouse CTLA4 
gene were: 5'(TTACTCTACTCCCTGAGGAGCTCAGCACATT- 
TGCC), and Y(TATACTTACCAGAATCCGGGCATGGTTCTG- 
GATCA). The primers used to amplify  mouse CD40 were: 5'(CGT- 
AGAGCTCACCATGGTGTCTTTGCCTCGGCTGTGCG), and 
3'(TATACTTACCCATCCGGGACTTTAAACCACAGATG). 
Chimeric Ig molecules expressing the extracellular portions of 
the mouse CTLA4 gene (10) or mouse CD40 gene (11) and the 
human IgG1 constant domains were created as follows. External 
primers encoding the 5' portion and the 3' portion of mouse CD40 
and CTLA4 were used to amplify  the extracellular  portion of  mouse 
CD40 (from mouse B cell cDNA),  and mouse CTLA4 (from a 
plasmid containing the mouse CTLA4 cDNA, kindly provided by 
Dr. Pierre Golstein, Centre d'Immunologie, INSERM-CNRS de 
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striction sites for subcloning into the human IgG1 expression vector 
(12), together with a 3' splice donor site within the 3' primer to 
correctly splice  to the human  71  exons. 
Transfection.  J558L hybridoma cells were transfected with pH 
APr-l-neo mCD40I~mCD8a and selected in the presence of  G418- 
sulphate (Gibco, Paisley, Scotland) or Xanthine (Sigma Chemical 
Co., St. Louis, MO) and mycophenolic acid (Calbiochem-Behring 
Corp., La JoUa, CA) (12). Cells were cultured at 5  ￿  104/ml.  Se- 
lection medium was added 24 h after the transfection, and clones 
were screened  (see Results  and Discussion)  when  they grew up 
2 wk later. 
Immunoprecipitation of mCD4OLmCD8ot  and Purification of Chi- 
meric Molecules.  Positive transfectant clones were adjusted to 4  x 
l&/ml cells in methionine-free media (Gibco) supplemented with 
10% dialyzed FCS with antibiotics, 2-ME, and glutamine supple- 
ments.  1 mCi of [3SS]methionine was added to  1 ml of cell  sus- 
pension,  and cells  were cultured  for 4  h  at 37~ 
After incubation, cells were washed thoroughly in PBS (pH 7.2) 
and lysed for 30 min at 4~  in 0.5% NP-40 containing buffer sup- 
plemented with PMSF (Sigma Chemical Co.). The lysate was spun 
at 10,000 g  for 10 min, the supematant removed, and precleared 
with protein A and protein G beads (Pharmacia, Uppsala, Sweden). 
The supernatant was aliquoted and incubated with either mCD40- 
Hyl prebound onto protein A beads or rat anti-mouse CD8 that 
had previously been bound onto protein G beads.  After washing, 
protein was eluted from the beads by boiling, and run under reducing 
and  nonreducing  conditions  on  12%  SDS-PAGE  gels. 
Antibodies andFlow Cytometry.  The mAbs used in these experi- 
ments were against human CD19 (HD37, Boehringer, Mannheim, 
Germany), human CD3 (TR66 [13]), human CD4 (10A12), human 
CD8 (OKT8; American Type Culture Collection, Rockville,  MD), 
human IgD (~5Ta4.1; American Type Culture Collection), mouse 
CD8 (53-6.72;  American Type Culture Collection), and mouse K 
(187.1  [14]). Fluorescent  second-step conjugates were goat anti- 
mouse IgM-PE (Southern Biotechnology Associates, Birmingham, 
AL), anti-mouse CD8 FITC (Becton Dickinson & Co., Mountain 
View,  CA),  mouse anti-rat  Ig FITC (Jackson ImmunoResearch 
Labs., Inc., West Grove, PA), sheep anti-mouse FITC (Silenus, Haw- 
thorn, Australia),  and goat anti-human IgM PE (Southern Biotech- 
nology Associates). 
Activated  B cells (5  x  10  s cells/well)  were stained with saturat- 
ing quantities of anti-CD19 mAb or chimeric constructs, followed 
after washing by second-step fluorescent reagents.  There was no 
detectable crossreactivity  between the reagents.  Cells were analyzed 
on a FACScan  |  instrument (Becton Dickinson & Co.). 5,000 gated 
B  or T  cells  were analyzed using  the Lysys software. 
Preparation of Human Pe@heral Lymphocytes and Murine Splenic 
B  Cells.  Lymphocytes from normal healthy human adults were 
separated from peripheral blood using Ficoll-Hypaque (Pharmacia 
Fine Chemicals, Piscataway,  NJ). Lymphocytes were cultured for 
2 h  at 37~  with 5% COJair to remove adherent cells. B lym- 
phocytes were purified using positive selection with magnetic beads. 
PBL  at  a  final  concentration  of  107/ml  were  incubated  with 
saturating quantities of anti-human CD19 mAb, HD37,  for i  h 
at 4~  After washing, B cells were positively selected by incubating 
the lymphocytes with sheep anti-mouse IgG-bound Dynabeads 
(Dynal, Oslo, Norway) as recommended by the manufacturer. After 
magnetic separation, the B cells were washed and incubated over- 
night at 37~  to allow the magnetic beads to dissociate from the 
B cells, in tissue culture medium (IMDM, supplemented with 10% 
FCS,  2 mM glutamine [Gibco], 100 IU/ml penicillin,  100/~g/ml 
streptomycin [Gibco], and 2-ME).  The resulting cell preparation 
was >98%  B cells  as assessed by FACS  |  (data not  shown). 
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Figure 1.  (a) Map of pH 3 APr-l-neo mCD40l~mCD8ot plasmid. (b) 
Predicted polypeptide sequence of the mCD40L-mCD8~ fusion protein 
showing the boundary amino acids between mouse CD8ot and mouse 
CD40L. (c) Immunoprecipitates from [3sS]methionine-labeled  J558L plas- 
macytoma cells that secreted mCD40L-mCD8c~,  run under nonreducing 
and reducing conditions on 12% SDS-PAGE. Lane 1, molecular weight 
markers; lane 2, the fusion protein precipitated under nonreducing condi- 
tions with mCD40I:H3,1-bound protein A beads; lane 3, immunoprecip- 
itation with a rat anti-mouse  CD8 mAb bound onto protein G beads; 
lanes 4-6, the same treatments from a gel run under reducing conditions. 
Murine B lymphocytes were prepared from 6-8-wk-old nude 
BALB/c female mice. Cell suspensions from minced spleens were 
centrifuged over Ficoll-Hypaque, washed, and then incubated for 
1 h  at 37~  in fiat-bottomed culture dishes  to remove adherent 
cells.  The resulting  preparation was >95%  B cells. 
Results and Discussion 
Construction and Characterization  of the mCD4OLmCD8c~ 
Chimeric Protein.  A soluble fusion protein between mCD40L 
and mouse CD8ot (mCD40L-mCD8o  0 was made as described 
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Figure  2.  FACS  |  analysis of mouse splenic lymphocytes from a normal 
euthymic mouse. (a) Cells were stained with supernatant from J558L cells 
that did not secrete mCD4OL-mCDScx, followed by goat anti-mouse IgM 
PE and rat anti-mouse CD8 FITC.  (b) Cells were stained as in a  except 
the first step included supernatant from the mCD4OL-mCD8o~-secreting 
J558L  clone. 
in Materials and Methods. PCR was used to amplify the ex- 
tracellular portion of CD40L from amino acid residues 50 
(Leucine)-260  of the published  cDNA sequence (5). This 
product was fused to the extracellular portion of a mouse 
cDNA encoding the CDSol polypeptide  from amino acid 
residues 1-165 (Leucine) (15), and the resulting PCR DNA 
product was subdoned into the expression vector pH/3 APt-1 
(Fig. 1 A). The sequence of the predicted fusion protein is 
shown in Fig. 1 b. The resulting plasmid (pH B APr-l-neo 
mCD40L-mCDSo~) was transfected by protoplast fusion into 
J588L, and G418-resistant clones were obtained. Transfectant 
clones that grew up were tested for secretion of the mCD40L- 
mCDSoe protein by an ELISA method; mouse CD40 linked 
to human IgG1 (mCD40-H3,1)  was immobilized on plates 
to capture chimeric protein from supernatants;  and an anti- 
body to mouse CD8 was used to identify the other 5' por- 
tion of the chimeric molecule. A strongly positive clone (6.4) 
thus obtained was metabolically labeled with [3SS]methio- 
nine. The labeled protein was precipitated either by rat anti- 
bodies to mouse CD8 bound onto protein G beads, or by 
mCD40-H~'I bound onto protein A beads. The results of 
this experiment are shown in Fig. I c. A single band of "~50 
kD is seen by both precipitation methods under reducing con- 
Figure 3.  Effect  of mCD40bmCD8c~  polypeptide  on mouse  B  cell 
proliferation. (a) Effect of mCD40bmCD8c~ or a control supematant alone 
or in conjunction with anti-lg-bound Sepharose beads on murine B cell 
proliferation.  105 B  cells were seeded per well,  with or without a fixed 
dose of anti-lg-bound beads,  and a varying dose of mCD40bmCD8c~. 
(b) Effect  of mCD40-H71  and  a  control construct  mCTLA4-H3"I  on 
mCD40bmCD8c~-induced  B cell proliferation, alone or in conjunction 
with an anti-lg stimulus.  Resuhs are representative of three separate e~- 
periments.  SEM were <10%. 
ditions;  nonreducing conditions  showed  the existence of 
monomers, trimers,  and higher molecular mass species, as 
has been reported for constructs encoding the extraceUular 
portion of CD8a (9). 
mCD4OL.mCD8ar Binds to Human and Mouse B Cells.  To 
test whether the chimeric protein mCD40bmCD8c~ would 
bind  to B cell CD40,  mouse splenic lymphocytes  from a 
normal euthymic mouse were incubated with supernatant from 
6.4 or a supernatant  from control J558L cells, followed by 
incubation with the second-step reagents anti-mouse CD8 
FITC or PE-conjugated goat anti-mouse IgM. Cells treated 
with the mCD40L-mCD8c~ showed CD8 positivity  of the 
B cell population,  indicating that mCD40L-mCD8c~ bound 
to B cells. This was not mediated by the CD8 part of the 
chimeric protein binding,  as MHC  class I-positive CD4- 
positive cells did not stain (Fig. 2 b). The control showed no 
binding to B cells (Fig. 2 a). There were distinct IgM-positive 
B cell and CD8-positive T cell  populations as expected. Human 
B cell lines also bind mCD40L-mCD8c~ (data not shown), 
as would be predicted by the fact that the mCD40L was orig- 
inally cloned using soluble human CD40 (5). 
mCD4ObmCD8cr  Stimulates  Mouse  and  Human  B  Cell 
Proliferation, Particularly  in Conjunction with Anti-Ig.  In humans, 
mAbs to CD40 have been shown to augment B cell prolifer- 
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anti-IgD, on the proliferation and size of human PBL as assessed  by for- 
ward scatter. (a) Shows the forward scatter of gated human B cells after 
culture in medium only. mCD40L-mCD8~, or mCD40L-mCD8c~ and 
anti-IgD added at a final concentration of 10/~g/ml. Soluble  anti-lgD 
did not cause  B call enlargement at this dose. (b) Shows  the forward  scatter 
of gated human T cells  after culture in medium only, mCD40L-mCD8c~, 
or mCD40L-mCD8cz and anti-lgD added at a final concentration of 10 
~g/ml.  (c) Effect of mCD40-H3,1 and mCTLA4-H"/1 on mCD40b 
mCD8cx-induced  human B call  proliferation alone  or in conjunction  with 
soluble anti-lgD. The results are representative  of three different experi- 
ments. SEM were <10%. 
ation initiated by anti-Ig  (4).  We therefore tested our chi- 
meric molecule in functional assays. The dose-dependent effect 
of mCD40L-mCD8o~ on mouse B cell proliferation is shown 
in  Fig.  3  a.  mCD40bmCD8ol  alone  stimulated  signifi- 
cant DNA synthesis (measured by [3H]thymidine incorpo- 
ration)  compared with that  found with  a coritrol superna- 
tant.  A comparable level of DNA synthesis was achieved by 
anti-Ig immobilized on Sepharose beads, mCD40L-mCDSoL 
together with anti-Ig  stimulated significantly higher  levels 
of  [3H]thymidine  uptake  (10-20-fold  higher  than  either 
stimulus alone) and this was accompanied by a large increase 
in B cell numbers. Such very high levels of proliferation could 
not be achieved by increasing  the dose of either  anti-Ig  or 
mCD40L-mCD8cz  alone,  indicating  that  they were syner- 
gistic.  The proliferative  effect of mCD40I:mCD8oL on mouse 
B cells was specially inhibited by soluble mCD40-H3,1 but 
not inhibited by an irrelevant fusion protein, mCTLA4-H3d 
(Fig.  3 b). The effect of the chimeric protein was therefore 
to the mCD40L and not mediated by CD8 binding to MHC 
class  I. 
Human peripheral  blood B cells also proliferated  in response 
to soluble anti-IgD and mCD40L-mCD8ot, and in addition, 
there was a significant  degree of proliferation with mCD40L- 
mCD8ol alone (Fig. 4 c). The addition of mCD40-H3,1 pro- 
foundly inhibited the proliferative effect mCD40L-mCDSc~, 
whereas mCTLA4-Hyl induced only partial inhibition. Anal- 
ysis of forward scatter of human PBL activated with mCD40L- 
mCD8cz alone induced a small increase in the size of human 
B cells. A few B cells appeared to be activated further. These 
cells were not aggregated but represented large B cell blasts. 
Soluble anti-Ig  had no discernible effect. However, anti-Ig 
and mCD40L-mCD8o~ together caused virtually all B cells 
to  enlarge  (Fig.  4 a).  T  cells  were unaffected  (Fig.  4  b). 
We have generated a soluble form of the type II membrane 
protein mCD40L by fusing the extracellular  portion of mouse 
CD8 with the extracellular portion of mCD40L.  This pro- 
tein  not  only bound to B  cells,  but it  also exerted specific 
effects on them. mCD40L-mCD8ol was potently synergistic 
with anti-Ig in stimulating B cells to proliferate, with large 
clumps of dividing cells forming in cultures that had received 
both  stimuli.  A  similar result  has  been reported for mAbs 
to CD40, which induce homotypic adhesion (16).  The po- 
tent synergy between anti-Ig and mCD40L-mCD8ol suggests 
that  they provide distinct  signals.  Soluble CD40L has been 
useful for dissecting the distinct signals that T cells must de- 
liver  to  support  effective B cell activation.  It will now be 
important  to determine where and on which cells CD40L 
is normally expressed in vivo, and the membranes that regu- 
late  CD40L  expression on resting  T  lymphocytes. 
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